Catarina Träger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Catarina Träger has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Anders Ståhlberg
Department of Laboratory Medicine, Sahlgrenska Center for Cancer Research, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
25 shared publications - Anna Djos
Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. 9
25 shared publications - Bengt Hallberg
Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
25 shared publications - Bronte Manouk Verhoeven
Childhood Cancer Research Unit, Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden. 6
25 shared publications - Christoffer Vannas
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital,Gothenburg, Region Vastra Gotaland, Sweden; Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
25 shared publications - Diana Treis
Karolinska Institutet
25 shared publications
Latest Publications
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary data 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Supplementary data 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary data 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Supplementary data 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Supplementary figures 1-4, supplementary tables 1-4, and supplementary case information
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Supplementary figures 1-4, supplementary tables 1-4, and supplementary case information
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Sanger sequencing of tumor and germline DNA
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Sanger sequencing of tumor and germline DNA
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Levels of oncogenic ALK mutations in tissue samples
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Levels of oncogenic ALK mutations in tissue samples
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary data 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Sequencing results, ALK hotspot mutation sites
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary data 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Sequencing results, ALK hotspot mutation sites
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Genomic profiles of tumor DNA generated by SNP microarray
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Genomic profiles of tumor DNA generated by SNP microarray
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Coverage with the NB-ALK sequencing panel
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Coverage with the NB-ALK sequencing panel
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary data 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Supplementary data 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary data 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Supplementary data 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Detection of relapse with ctDNA analysis 9 months prior to clinical presentation in a patient (patient 2) with ALK p.R1275Q-positive neuroblastoma treated with lorlatinib. A, MIBG scans. B, Levels of ctDNA. C, NSE. CS, Curie score; ND, not detected; TID, temozolomide, irinotecan and dinutuximab; URL, upper reference limit (16.3 µg/L).
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Detection of relapse with ctDNA analysis 9 months prior to clinical presentation in a patient (patient 2) with ALK p.R1275Q-positive neuroblastoma treated with lorlatinib. A, MIBG scans. B, Levels of ctDNA. C, NSE. CS, Curie score; ND, not detected; TID, temozolomide, irinotecan and dinutuximab; URL, upper reference limit (16.3 µg/L).
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Lasting response to lorlatinib in a patient (patient 1) with relapsed neuroblastoma harboring ALK p.R1275Q. A, Chest computed tomography (top) and MIBG scans (bottom) at time of initial diagnosis, at relapse, and after 2 months of lorlatinib treatment. Red arrows denote tumors. B, Levels of ctDNA during and after lorlatinib treatment. ND, not detected. C, Chromogranin A. URL, upper reference limit (102 µg/L). NSE, urine VMA and urine HVA were within normal ranges at time of relapse and were therefore not further analyzed. HVA, homovanillic acid; VMA, vanillylmandelic acid.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Lasting response to lorlatinib in a patient (patient 1) with relapsed neuroblastoma harboring ALK p.R1275Q. A, Chest computed tomography (top) and MIBG scans (bottom) at time of initial diagnosis, at relapse, and after 2 months of lorlatinib treatment. Red arrows denote tumors. B, Levels of ctDNA during and after lorlatinib treatment. ND, not detected. C, Chromogranin A. URL, upper reference limit (102 µg/L). NSE, urine VMA and urine HVA were within normal ranges at time of relapse and were therefore not further analyzed. HVA, homovanillic acid; VMA, vanillylmandelic acid.